Phase 1 Trials: Therapy, Not Just Science
Phase 1 trials should be considered therapeutic options for some patients.
Phase 1 trials should be considered therapeutic options for some patients.
African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
Novel algorithms may be able to diagnose and plan cancer treatments more effectively than humans, but it’s unclear if and when artificial intelligence will be integrated into clinical practice.
Access to treatment should be considered as important as the research leading to clinical improvements.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
As more rare cancers are identified, the need for rethinking approaches to research will become greater.